A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment

Osimertinib is a third‐generation, irreversible, oral epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR‐TKI sensitizing and EGFR T790M and has demonstrated efficacy in non‐small cell lung cancer (NSCLC) central nervous system met...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pharmacol Res Perspect
Main Authors: Vishwanathan, Karthick, Sanchez‐Simon, Inmaculada, Keam, Bhumsuk, Penel, Nicolas, de Miguel‐Luken, Maria, Weilert, Doris, Mills, Andrew, Marotti, Marcelo, Johnson, Martin, Ravaud, Alain
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7307240/
https://ncbi.nlm.nih.gov/pubmed/32567817
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.613
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados